C

ome Friday morning, Amgen will reveal whether its costly, much-discussed new cholesterol drug will live up to blockbuster expectations — or become a cautionary tale in biopharma lore.

At the American Cardiology Conference in Washington, D.C., Amgen will present results from a 27,000-patient study determining whether its drug can reduce patients’ risk of heart attack and stroke, with sweeping ramifications for payers, patients, investors, and pharma.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • My cholesterol in September of 2016 was 240 and my LDL was 167 and here in March of 2017 after only 3 injections of Praluent 75 mg. My cholesterol is now 114 and my LDL is 37. Pretty amazing

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X